Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGENONMELA balstilimab in advanced non-melanoma skin cancers
2024-517380-22-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of balstilimab in basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and non-melanoma skin cancer (NMSC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Clinical benefit rate (CBR) by RECIST v1.1. Planned start Nov 2024; status: authorised.
02
Drugs
balstilimab
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on 2024-517380-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517380-22-00.